{"ticker": {"uuid": "dd0f68e3-5227-4be5-9880-535c3c1a5012", "symbol": "MENS", "name": "Jyong Biotech Ltd. Ordinary Shares", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Doctor shares the \u2018most troubling trend\u2019 in men\u2019s health \u2014 and why biohacking is to blame", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxNc2pXQVMyXzdmNFRkSDdjZ1dWUlNOZXZPc0p1QUpxaDRmclMzbVRzOGxhUWxnVTZ1b1pNMlBlYk9HVlVZekUzTjlGblFvT19uY2NOQnNkeHBVZGE2bVFHYlZQLXQweGtodlVKVDBpYUFZSklXVkZ3MmRSb0xTMHo4czNJaC03ZnNSc184cklzYkZXckN5RXc?oc=5", "source_name": "New York Post", "published_at": "2026-07-10T15:26:00+00:00", "published_display": "10 Jul 2026 15:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jyong Biotech presents drug candidate at BIO 2026 convention", "summary": "Jyong Biotech participated in the BIO International Convention, presenting its botanical drug candidate, Botreso (API-1), for benign prostatic hyperplasia. The company is preparing a New Drug Application and pursuing global licensing, actively discussing commercialization with ph", "url": "https://www.investing.com/news/company-news/jyong-biotech-presents-drug-candidate-at-bio-2026-convention-93CH-4773043", "source_name": "Investing.com", "published_at": "2026-07-02T13:15:30", "published_display": "02 Jul 2026 13:15", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jyong Biotech advances botanical drug Botreso\u00ae at BIO 2026, targeting global licensing for BPH treatment.", "summary": "Jyong Biotech showcased its botanical drug candidate Botreso\u00ae at BIO 2026, demonstrating its potential for treating benign prostatic hyperplasia (BPH) and lower urinary tract symptoms through successful Phase III trials. The company is preparing its New Drug Application and activ", "url": "https://pluang.com/en/news-feed/jyong-biotech-pamerkan-portofolio-obat-botani-di-konvensi-internasional-bio-2026", "source_name": "Pluang", "published_at": "2026-07-02T12:15:30", "published_display": "02 Jul 2026 12:15", "sentiment": "positive", "sentiment_pct": 87, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jyong Biotech pitched its plant-based BPH drug to pharma partners at BIO 2026", "summary": "Jyong Biotech (Nasdaq: MENS) showcased its botanical drug portfolio, including the Phase III candidate Botreso (API-1) for benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS), at the BIO 2026 International Convention. The company is actively pursuing global", "url": "https://www.stocktitan.net/news/MENS/jyong-biotech-showcases-botanical-drug-portfolio-at-bio-2026-sdssz1mooene.html", "source_name": "Stock Titan", "published_at": "2026-07-02T12:15:30", "published_display": "02 Jul 2026 12:15", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jyong Biotech Showcases Botanical Drug Portfolio at BIO 2026 International Convention", "summary": "Jyong Biotech showcased its botanical drug portfolio, including its lead candidate Botreso\u00ae, at the BIO 2026 International Convention. The company is actively pursuing global licensing discussions for Botreso\u00ae, which targets benign prostatic hyperplasia (BPH) and lower urinary tr", "url": "https://www.globenewswire.com/news-release/2026/07/02/3321286/0/en/jyong-biotech-showcases-botanical-drug-portfolio-at-bio-2026-international-convention.html", "source_name": "GlobeNewswire", "published_at": "2026-07-02T12:15:30", "published_display": "02 Jul 2026 12:15", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Jyong Biotech Ltd. \u2013 NASDAQ:MENS", "summary": "This article provides financial information for Jyong Biotech Ltd. (NASDAQ: MENS), specifically focusing on its price-to-book forward ratio. It notes that the market is currently closed with no trades recorded.", "url": "https://www.tradingview.com/symbols/NASDAQ-MENS/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T01:39:27", "published_display": "27 Jun 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Jyong Biotech Ltd. \u2013 NASDAQ:MENS", "summary": "This page provides information about the Price to Sales Forward metric for Jyong Biotech Ltd. (NASDAQ: MENS). It confirms that the market is closed, with no trades, and the data is provided by ICE Data Services and FactSet.", "url": "https://www.tradingview.com/symbols/NASDAQ-MENS/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T20:39:56", "published_display": "26 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Jyong Biotech Ltd. \u2013 NASDAQ:MENS", "summary": "This article provides financial information for Jyong Biotech Ltd. (NASDAQ:MENS), specifically focusing on its enterprise value to EBIT forward. It indicates available data on this metric, reflecting current financial health and forward-looking valuation.", "url": "https://www.tradingview.com/symbols/NASDAQ-MENS/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T18:11:50", "published_display": "25 Jun 2026 18:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jyong Biotech Ltd (MENS) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Jyong Biotech Ltd (MENS), covering its support, resistance levels, and various technical indicators. It details individual indicator values like MACD, RSI, and moving averages (MA5, MA10, MA20, MA50, MA100, MA200), offering a summary ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mens/technical", "source_name": "TradingKey", "published_at": "2026-06-23T13:40:36", "published_display": "23 Jun 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jyong Biotech Ltd (MENS) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Jyong Biotech Ltd (MENS) dividend and stock split history, indicating that no dividends have been distributed in the past 5 years and no stock splits have occurred. It also presents basic stock information like its current trading price, marke", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mens/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T21:40:33", "published_display": "17 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jyong Biotech Ltd (MENS) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Jyong Biotech Ltd (MENS), listing major individual and institutional holders. Key shareholders include Perfect Minds Co Ltd, Laxton Investments Company Ltd, and Linkage Gladden Enterprise Ltd, alongside a breakdown by shareholder ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mens/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T16:10:09", "published_display": "17 Jun 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jyong Biotech Ltd (MENS) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for Jyong Biotech Ltd (MENS), covering its stock performance and various risk metrics. It includes financial data such as market capitalization, daily returns, volatility, and liquidity, but several specific figures are listed as \"\u2014\" or \"0.", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mens/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-17T15:42:05", "published_display": "17 Jun 2026 15:42", "sentiment": "negative", "sentiment_pct": 40, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jyong Biotech Ltd (MENS) Institutional Confidence", "summary": "This article from TradingKey provides details on the institutional confidence in Jyong Biotech Ltd (MENS), listing key shareholders and their holdings. The stock closed at $1.590 with a minor dip and has a market cap of $121.64M. The institutional shareholding data shows several ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mens/sentiment", "source_name": "TradingKey", "published_at": "2026-06-16T18:40:39", "published_display": "16 Jun 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jyong Biotech Ltd (MENS) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for Jyong Biotech Ltd (MENS), detailing its current stock price, market cap, and trading performance. It notes that key valuation metrics such as P/E, P/B, P/S, and P/CF have not been disclosed by the company. The article serves as a bri", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mens/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-16T16:40:39", "published_display": "16 Jun 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Certain Ordinary Shares of Jyong Biotech Ltd. are subject to a Lock-Up Agreement Ending on 16-JUN-2026.", "summary": "Certain ordinary shares of Jyong Biotech Ltd. are under a lock-up agreement set to expire on June 16, 2026. This lock-up period, starting from June 16, 2025, affects directors, officers, and holders of more than 5% of outstanding shares for 365 days, while holders of less than 5%", "url": "https://www.marketscreener.com/news/certain-ordinary-shares-of-jyong-biotech-ltd-are-subject-to-a-lock-up-agreement-ending-on-16-jun-20-ce7f5cded08cf226", "source_name": "www.marketscreener.com", "published_at": "2026-06-16T02:10:48", "published_display": "16 Jun 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JYONG BIOTECH LTD (MENS) Stock Chart", "summary": "The article provides a stock chart for JYONG BIOTECH LTD (MENS), listed on NASDAQ. As of June 9, 2026, at 01:23 PM, the stock price was 1.85 USD, down 0.15 (-7.5%). The page offers various tools and data for stock analysis.", "url": "https://www.chartmill.com/stock/quote/MENS/stock-chart", "source_name": "ChartMill", "published_at": "2026-06-05T17:39:17", "published_display": "05 Jun 2026 17:39", "sentiment": "negative", "sentiment_pct": 31, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MENS - Jyong Biotech Ltd Stock Price and Quote", "summary": "This article provides detailed stock information for Jyong Biotech Ltd (MENS), including its last closing price, financial metrics, performance indicators, and recent news announcements. It covers key data such as market capitalization, P/E ratios, employee count, and details abo", "url": "https://finviz.com/stock?t=MENS", "source_name": "Finviz", "published_at": "2026-05-30T14:39:47", "published_display": "30 May 2026 14:39", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jyong Biotech outlines FDA approval path for botanical drug Botreso\u00ae targeting benign prostatic hyperplasia.", "summary": "Jyong Biotech's CEO, Fu-Feng Kuo, detailed the company's strategy to secure FDA approval for Botreso\u00ae, a botanical drug for benign prostatic hyperplasia (BPH) affecting over 12 million men in the US. The company has completed pivotal studies, showing a strong safety profile, and ", "url": "https://pluang.com/en/news-feed/strategi-global-jyong-biotech-dan-jalur-fda", "source_name": "Pluang", "published_at": "2026-05-29T13:39:02", "published_display": "29 May 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live Interview", "summary": "Jyong Biotech's CEO, Ms. Fu-Feng Kuo, detailed the company's FDA pathway and global strategy in a PharmaBoardroom interview. The company is developing plant-derived therapeutics, notably Botreso\u00ae for benign prostatic hyperplasia (BPH), and emphasizes a strong focus on the U.S. ma", "url": "https://www.globenewswire.com/news-release/2026/05/29/3303550/0/en/jyong-biotech-ceo-outlines-fda-pathway-and-global-strategy-in-pharmaboardroom-live-interview.html", "source_name": "GlobeNewswire", "published_at": "2026-05-29T12:00:46", "published_display": "29 May 2026 12:00", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "12M Americans have BPH; one biotech is testing a plant-based option", "summary": "Jyong Biotech is advancing Botreso, a plant-based drug targeting benign prostatic hyperplasia (BPH) with 12.2 million US patients, and a prostate cancer prevention asset, PCP. The company highlighted its FDA pathway, which includes additional US studies, aiming for a combined NDA", "url": "https://www.stocktitan.net/news/MENS/jyong-biotech-ceo-outlines-fda-pathway-and-global-strategy-in-pharma-16ak0vr1bgj3.html", "source_name": "Stock Titan", "published_at": "2026-05-29T11:59:46", "published_display": "29 May 2026 11:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jyong Biotech (Nasdaq:MENS) - Stock Analysis", "summary": "Jyong Biotech (Nasdaq:MENS) is a science-driven biotechnology company developing plant-derived drugs for urinary system diseases. The company reported a delayed 20-F filing and provided updates on its botanical drugs, Botreso, PCP (MCS-8), and MCS-2, highlighting their clinical e", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mens/jyong-biotech", "source_name": "Simply Wall Street", "published_at": "2026-05-28T12:39:49", "published_display": "28 May 2026 12:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year Ended December 31, 2025", "summary": "Jyong Biotech Ltd. announced the filing of its annual report on Form 20-F for the fiscal year ending December 31, 2025, with the U.S. SEC on May 14, 2026. The Taiwan-based biotechnology company specializes in developing plant-derived therapeutics for urinary system diseases and o", "url": "https://www.quiverquant.com/news/Jyong+Biotech+Ltd.+Files+Annual+Report+on+Form+20-F+for+Fiscal+Year+Ended+December+31,+2025", "source_name": "Quiver Quantitative", "published_at": "2026-05-15T12:44:00", "published_display": "15 May 2026 12:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inside Jyong Biotech's 2025 SEC annual report filing for investors", "summary": "Jyong Biotech (Nasdaq: MENS) announced the filing of its Form 20-F annual report for the fiscal year ended December 31, 2025, with the SEC on May 14, 2026. The report is accessible on the company\u2019s investor relations site and the SEC website, detailing key financial figures like ", "url": "https://www.stocktitan.net/news/MENS/jyong-biotech-ltd-files-annual-report-on-form-20-f-for-fiscal-year-liwn99movhcd.html", "source_name": "Stock Titan", "published_at": "2026-05-15T12:39:42", "published_display": "15 May 2026 12:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025", "summary": "Jyong Biotech Ltd. announced it filed its annual report on Form 20-F for the fiscal year ended December 31, 2025, with the U.S. Securities and Exchange Commission on May 14, 2026. The report is accessible on the company's investor relations website and the SEC's website, with har", "url": "https://www.globenewswire.com/news-release/2026/05/15/3295834/0/en/jyong-biotech-ltd-files-annual-report-on-form-20-f-for-fiscal-year-2025.html", "source_name": "GlobeNewswire", "published_at": "2026-05-15T12:39:42", "published_display": "15 May 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Jyong Biotech Delays Annual 20-F (Yearly Report)", "summary": "Jyong Biotech Ltd. (MENS) has announced a delay in filing its annual Form 20-F for the fiscal year ending December 31, 2025, due to additional time needed to finalize audited financial statements. The company anticipates filing within 15 calendar days of the original due date and", "url": "https://www.tipranks.com/news/company-announcements/jyong-biotech-delays-annual-20-f-yearly-report", "source_name": "TipRanks", "published_at": "2026-04-29T18:10:15", "published_display": "29 Apr 2026 18:10", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jyong Biotech Updates Market Access Strategy for Innovative", "summary": "Jyong Biotech announced advancements in its market access strategies for innovative plant-based drugs, Botreso and PCP, based on their clinical efficacy and competitive advantages. The company highlights the excellent safety profile, potential for prostate cancer prevention, and ", "url": "https://www.globenewswire.com/de/news-release/2026/04/28/3282657/0/en/jyong-biotech-updates-market-access-strategy-for-innovative-botanical-drugs-establishing-multiple-competitive-advantages-for-new-drug-portfolio.html", "source_name": "GlobeNewswire", "published_at": "2026-04-29T01:09:20", "published_display": "29 Apr 2026 01:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jyong Biotech Updates Market Access Strategy for Innovative Botanical Drugs, Establishing Multiple Competitive Advantages for New Drug Portfolio", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/jyong-biotech-updates-market-access-000000493.html", "source_name": "PR Newswire", "published_at": "2026-04-29T00:00:00+00:00", "published_display": "29 Apr 2026 00:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Two plant-based prostate drug candidates move toward broader markets", "summary": "Jyong Biotech has advanced market access strategies for its botanical drugs Botreso and PCP, emphasizing their clinical efficacy, safety, and competitive advantages in manufacturing. Both drugs aim to address prostate health, with Botreso completing Phase III trials and PCP finis", "url": "https://www.stocktitan.net/news/MENS/jyong-biotech-updates-market-access-strategy-for-innovative-ubkj6k5p43gc.html", "source_name": "Stock Titan", "published_at": "2026-04-28T12:38:55", "published_display": "28 Apr 2026 12:38", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Short Interest in Jyong Biotech Ltd. (NASDAQ:MENS) Decreases By 43.2%", "summary": "Short interest in Jyong Biotech Ltd. (NASDAQ:MENS) significantly decreased by 43.2% in April, totaling 133,023 shares, which represents about 0.2% of its outstanding shares. This decline brings the short-interest ratio to approximately 1.0 days. Despite institutional investors li", "url": "https://www.marketbeat.com/instant-alerts/short-interest-in-jyong-biotech-ltd-nasdaqmens-decreases-by-432-2026-04-27/", "source_name": "MarketBeat", "published_at": "2026-04-28T01:39:27", "published_display": "28 Apr 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CEO Fu-Feng Kuo, Jyong Biotech Ltd.'s (NASDAQ:MENS) largest shareholder sees value of holdings go down 23% after recent drop", "summary": "", "url": "https://news.google.com/rss/articles/CBMidkFVX3lxTFBlQ1RRS0JuWHhUclVxSklTUi1VY3ZYSHlGd1BuUlVtdHBUbWtqVWNSR0cyZGxLbXBENFVFN2huNl9PRVhOVTI1cHNKS2lUUHB6SzFaQTBoazl5NV9OZmY2OGxFUXFXSDhRSzFJbHRIcHAwQmtybGc?oc=5", "source_name": "Market source", "published_at": "2026-02-10T08:00:00+00:00", "published_display": "10 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "After the recent decline, Jyong Biotech Ltd. (NASDAQ:MENS) CEO Fu-Feng Kuo's holdings have lost 33% of their value", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-29T08:00:00+00:00", "published_display": "29 Dec 2025 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jyong Biotech Responds to Share Price and Volume Movement", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxNbWNIS182Q0J3WTB4by13Mjk0ZjJtV2hUdVVKMTd0TlVGNEM0OFF6T01DYWllZVZFN2d3cEZ0T090cU41WWR0bjhCNlhtNkdrcDdHdTJTSGNRWTlUUGg2RXFad2ZYWndBWWlGeHFRdUhiNVd1SWlYN1lWdGc5Z3licU83MTFKNEFCVTV3UFVrSW5CMV8yUjJvR0NIck1zZG5XdWRjSkhKQzBCOTB5UEkzNHlVWl9DaVFHYnlfT2pQMG45UFhYVXNKeg?oc=5", "source_name": "GlobeNewswire", "published_at": "2025-12-19T08:00:00+00:00", "published_display": "19 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MENS Stock Price and Chart \u2014 NASDAQ:MENS", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE92bl9mOFBlOWpFNFVIR080ZUpPZ1JQN2tyM1N4Q2RXNEVjMW9mT0RIaEliUHRFOTVQdzBtTGVxQ1RVcEQ3ZkppVThWNjNRX05oT2NBZlR5R0w5Z0pC?oc=5", "source_name": "TradingView", "published_at": "2025-09-12T07:00:00+00:00", "published_display": "12 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy Jyong Biotech Ltd. (MENS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE1CaHl5SGNwX1JGVnZlaS1XdmRHS3dyRDBJSzhFLUx1aTFtTXR5TDdQcUVwaWQ2QXJ4NTZqSzRSeGRmcDJxa0VmbHhXV3VPWW05RW9BbHpBSTluU1F1cE01ZkxpbmRpZng5X3NJSw?oc=5", "source_name": "Zacks Investment Research", "published_at": "2025-07-31T20:22:27+00:00", "published_display": "31 Jul 2025 20:22", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Doctor shares the \u2018most troubling trend\u2019 in men\u2019s health \u2014 and why biohacking is to blame", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxNc2pXQVMyXzdmNFRkSDdjZ1dWUlNOZXZPc0p1QUpxaDRmclMzbVRzOGxhUWxnVTZ1b1pNMlBlYk9HVlVZekUzTjlGblFvT19uY2NOQnNkeHBVZGE2bVFHYlZQLXQweGtodlVKVDBpYUFZSklXVkZ3MmRSb0xTMHo4czNJaC03ZnNSc184cklzYkZXckN5RXc?oc=5", "source_name": "New York Post", "published_at": "2026-07-10T15:26:00+00:00", "published_display": "10 Jul 2026 15:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jyong Biotech presents drug candidate at BIO 2026 convention", "summary": "Jyong Biotech participated in the BIO International Convention, presenting its botanical drug candidate, Botreso (API-1), for benign prostatic hyperplasia. The company is preparing a New Drug Application and pursuing global licensing, actively discussing commercialization with ph", "url": "https://www.investing.com/news/company-news/jyong-biotech-presents-drug-candidate-at-bio-2026-convention-93CH-4773043", "source_name": "Investing.com", "published_at": "2026-07-02T13:15:30", "published_display": "02 Jul 2026 13:15", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jyong Biotech advances botanical drug Botreso\u00ae at BIO 2026, targeting global licensing for BPH treatment.", "summary": "Jyong Biotech showcased its botanical drug candidate Botreso\u00ae at BIO 2026, demonstrating its potential for treating benign prostatic hyperplasia (BPH) and lower urinary tract symptoms through successful Phase III trials. The company is preparing its New Drug Application and activ", "url": "https://pluang.com/en/news-feed/jyong-biotech-pamerkan-portofolio-obat-botani-di-konvensi-internasional-bio-2026", "source_name": "Pluang", "published_at": "2026-07-02T12:15:30", "published_display": "02 Jul 2026 12:15", "sentiment": "positive", "sentiment_pct": 87, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jyong Biotech pitched its plant-based BPH drug to pharma partners at BIO 2026", "summary": "Jyong Biotech (Nasdaq: MENS) showcased its botanical drug portfolio, including the Phase III candidate Botreso (API-1) for benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS), at the BIO 2026 International Convention. The company is actively pursuing global", "url": "https://www.stocktitan.net/news/MENS/jyong-biotech-showcases-botanical-drug-portfolio-at-bio-2026-sdssz1mooene.html", "source_name": "Stock Titan", "published_at": "2026-07-02T12:15:30", "published_display": "02 Jul 2026 12:15", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jyong Biotech Showcases Botanical Drug Portfolio at BIO 2026 International Convention", "summary": "Jyong Biotech showcased its botanical drug portfolio, including its lead candidate Botreso\u00ae, at the BIO 2026 International Convention. The company is actively pursuing global licensing discussions for Botreso\u00ae, which targets benign prostatic hyperplasia (BPH) and lower urinary tr", "url": "https://www.globenewswire.com/news-release/2026/07/02/3321286/0/en/jyong-biotech-showcases-botanical-drug-portfolio-at-bio-2026-international-convention.html", "source_name": "GlobeNewswire", "published_at": "2026-07-02T12:15:30", "published_display": "02 Jul 2026 12:15", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Jyong Biotech Ltd. \u2013 NASDAQ:MENS", "summary": "This article provides financial information for Jyong Biotech Ltd. (NASDAQ: MENS), specifically focusing on its price-to-book forward ratio. It notes that the market is currently closed with no trades recorded.", "url": "https://www.tradingview.com/symbols/NASDAQ-MENS/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T01:39:27", "published_display": "27 Jun 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Jyong Biotech Ltd. \u2013 NASDAQ:MENS", "summary": "This page provides information about the Price to Sales Forward metric for Jyong Biotech Ltd. (NASDAQ: MENS). It confirms that the market is closed, with no trades, and the data is provided by ICE Data Services and FactSet.", "url": "https://www.tradingview.com/symbols/NASDAQ-MENS/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T20:39:56", "published_display": "26 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Jyong Biotech Ltd. \u2013 NASDAQ:MENS", "summary": "This article provides financial information for Jyong Biotech Ltd. (NASDAQ:MENS), specifically focusing on its enterprise value to EBIT forward. It indicates available data on this metric, reflecting current financial health and forward-looking valuation.", "url": "https://www.tradingview.com/symbols/NASDAQ-MENS/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T18:11:50", "published_display": "25 Jun 2026 18:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jyong Biotech Ltd (MENS) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Jyong Biotech Ltd (MENS), covering its support, resistance levels, and various technical indicators. It details individual indicator values like MACD, RSI, and moving averages (MA5, MA10, MA20, MA50, MA100, MA200), offering a summary ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mens/technical", "source_name": "TradingKey", "published_at": "2026-06-23T13:40:36", "published_display": "23 Jun 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jyong Biotech Ltd (MENS) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Jyong Biotech Ltd (MENS) dividend and stock split history, indicating that no dividends have been distributed in the past 5 years and no stock splits have occurred. It also presents basic stock information like its current trading price, marke", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mens/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T21:40:33", "published_display": "17 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jyong Biotech Ltd (MENS) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Jyong Biotech Ltd (MENS), listing major individual and institutional holders. Key shareholders include Perfect Minds Co Ltd, Laxton Investments Company Ltd, and Linkage Gladden Enterprise Ltd, alongside a breakdown by shareholder ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mens/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T16:10:09", "published_display": "17 Jun 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jyong Biotech Ltd (MENS) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for Jyong Biotech Ltd (MENS), covering its stock performance and various risk metrics. It includes financial data such as market capitalization, daily returns, volatility, and liquidity, but several specific figures are listed as \"\u2014\" or \"0.", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mens/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-17T15:42:05", "published_display": "17 Jun 2026 15:42", "sentiment": "negative", "sentiment_pct": 40, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jyong Biotech Ltd (MENS) Institutional Confidence", "summary": "This article from TradingKey provides details on the institutional confidence in Jyong Biotech Ltd (MENS), listing key shareholders and their holdings. The stock closed at $1.590 with a minor dip and has a market cap of $121.64M. The institutional shareholding data shows several ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mens/sentiment", "source_name": "TradingKey", "published_at": "2026-06-16T18:40:39", "published_display": "16 Jun 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jyong Biotech Ltd (MENS) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for Jyong Biotech Ltd (MENS), detailing its current stock price, market cap, and trading performance. It notes that key valuation metrics such as P/E, P/B, P/S, and P/CF have not been disclosed by the company. The article serves as a bri", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mens/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-16T16:40:39", "published_display": "16 Jun 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Certain Ordinary Shares of Jyong Biotech Ltd. are subject to a Lock-Up Agreement Ending on 16-JUN-2026.", "summary": "Certain ordinary shares of Jyong Biotech Ltd. are under a lock-up agreement set to expire on June 16, 2026. This lock-up period, starting from June 16, 2025, affects directors, officers, and holders of more than 5% of outstanding shares for 365 days, while holders of less than 5%", "url": "https://www.marketscreener.com/news/certain-ordinary-shares-of-jyong-biotech-ltd-are-subject-to-a-lock-up-agreement-ending-on-16-jun-20-ce7f5cded08cf226", "source_name": "www.marketscreener.com", "published_at": "2026-06-16T02:10:48", "published_display": "16 Jun 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JYONG BIOTECH LTD (MENS) Stock Chart", "summary": "The article provides a stock chart for JYONG BIOTECH LTD (MENS), listed on NASDAQ. As of June 9, 2026, at 01:23 PM, the stock price was 1.85 USD, down 0.15 (-7.5%). The page offers various tools and data for stock analysis.", "url": "https://www.chartmill.com/stock/quote/MENS/stock-chart", "source_name": "ChartMill", "published_at": "2026-06-05T17:39:17", "published_display": "05 Jun 2026 17:39", "sentiment": "negative", "sentiment_pct": 31, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MENS - Jyong Biotech Ltd Stock Price and Quote", "summary": "This article provides detailed stock information for Jyong Biotech Ltd (MENS), including its last closing price, financial metrics, performance indicators, and recent news announcements. It covers key data such as market capitalization, P/E ratios, employee count, and details abo", "url": "https://finviz.com/stock?t=MENS", "source_name": "Finviz", "published_at": "2026-05-30T14:39:47", "published_display": "30 May 2026 14:39", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jyong Biotech outlines FDA approval path for botanical drug Botreso\u00ae targeting benign prostatic hyperplasia.", "summary": "Jyong Biotech's CEO, Fu-Feng Kuo, detailed the company's strategy to secure FDA approval for Botreso\u00ae, a botanical drug for benign prostatic hyperplasia (BPH) affecting over 12 million men in the US. The company has completed pivotal studies, showing a strong safety profile, and ", "url": "https://pluang.com/en/news-feed/strategi-global-jyong-biotech-dan-jalur-fda", "source_name": "Pluang", "published_at": "2026-05-29T13:39:02", "published_display": "29 May 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live Interview", "summary": "Jyong Biotech's CEO, Ms. Fu-Feng Kuo, detailed the company's FDA pathway and global strategy in a PharmaBoardroom interview. The company is developing plant-derived therapeutics, notably Botreso\u00ae for benign prostatic hyperplasia (BPH), and emphasizes a strong focus on the U.S. ma", "url": "https://www.globenewswire.com/news-release/2026/05/29/3303550/0/en/jyong-biotech-ceo-outlines-fda-pathway-and-global-strategy-in-pharmaboardroom-live-interview.html", "source_name": "GlobeNewswire", "published_at": "2026-05-29T12:00:46", "published_display": "29 May 2026 12:00", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "12M Americans have BPH; one biotech is testing a plant-based option", "summary": "Jyong Biotech is advancing Botreso, a plant-based drug targeting benign prostatic hyperplasia (BPH) with 12.2 million US patients, and a prostate cancer prevention asset, PCP. The company highlighted its FDA pathway, which includes additional US studies, aiming for a combined NDA", "url": "https://www.stocktitan.net/news/MENS/jyong-biotech-ceo-outlines-fda-pathway-and-global-strategy-in-pharma-16ak0vr1bgj3.html", "source_name": "Stock Titan", "published_at": "2026-05-29T11:59:46", "published_display": "29 May 2026 11:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jyong Biotech (Nasdaq:MENS) - Stock Analysis", "summary": "Jyong Biotech (Nasdaq:MENS) is a science-driven biotechnology company developing plant-derived drugs for urinary system diseases. The company reported a delayed 20-F filing and provided updates on its botanical drugs, Botreso, PCP (MCS-8), and MCS-2, highlighting their clinical e", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mens/jyong-biotech", "source_name": "Simply Wall Street", "published_at": "2026-05-28T12:39:49", "published_display": "28 May 2026 12:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year Ended December 31, 2025", "summary": "Jyong Biotech Ltd. announced the filing of its annual report on Form 20-F for the fiscal year ending December 31, 2025, with the U.S. SEC on May 14, 2026. The Taiwan-based biotechnology company specializes in developing plant-derived therapeutics for urinary system diseases and o", "url": "https://www.quiverquant.com/news/Jyong+Biotech+Ltd.+Files+Annual+Report+on+Form+20-F+for+Fiscal+Year+Ended+December+31,+2025", "source_name": "Quiver Quantitative", "published_at": "2026-05-15T12:44:00", "published_display": "15 May 2026 12:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inside Jyong Biotech's 2025 SEC annual report filing for investors", "summary": "Jyong Biotech (Nasdaq: MENS) announced the filing of its Form 20-F annual report for the fiscal year ended December 31, 2025, with the SEC on May 14, 2026. The report is accessible on the company\u2019s investor relations site and the SEC website, detailing key financial figures like ", "url": "https://www.stocktitan.net/news/MENS/jyong-biotech-ltd-files-annual-report-on-form-20-f-for-fiscal-year-liwn99movhcd.html", "source_name": "Stock Titan", "published_at": "2026-05-15T12:39:42", "published_display": "15 May 2026 12:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025", "summary": "Jyong Biotech Ltd. announced it filed its annual report on Form 20-F for the fiscal year ended December 31, 2025, with the U.S. Securities and Exchange Commission on May 14, 2026. The report is accessible on the company's investor relations website and the SEC's website, with har", "url": "https://www.globenewswire.com/news-release/2026/05/15/3295834/0/en/jyong-biotech-ltd-files-annual-report-on-form-20-f-for-fiscal-year-2025.html", "source_name": "GlobeNewswire", "published_at": "2026-05-15T12:39:42", "published_display": "15 May 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jyong Biotech Delays Annual 20-F (Yearly Report)", "summary": "Jyong Biotech Ltd. (MENS) has announced a delay in filing its annual Form 20-F for the fiscal year ending December 31, 2025, due to additional time needed to finalize audited financial statements. The company anticipates filing within 15 calendar days of the original due date and", "url": "https://www.tipranks.com/news/company-announcements/jyong-biotech-delays-annual-20-f-yearly-report", "source_name": "TipRanks", "published_at": "2026-04-29T18:10:15", "published_display": "29 Apr 2026 18:10", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jyong Biotech Updates Market Access Strategy for Innovative", "summary": "Jyong Biotech announced advancements in its market access strategies for innovative plant-based drugs, Botreso and PCP, based on their clinical efficacy and competitive advantages. The company highlights the excellent safety profile, potential for prostate cancer prevention, and ", "url": "https://www.globenewswire.com/de/news-release/2026/04/28/3282657/0/en/jyong-biotech-updates-market-access-strategy-for-innovative-botanical-drugs-establishing-multiple-competitive-advantages-for-new-drug-portfolio.html", "source_name": "GlobeNewswire", "published_at": "2026-04-29T01:09:20", "published_display": "29 Apr 2026 01:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jyong Biotech Updates Market Access Strategy for Innovative Botanical Drugs, Establishing Multiple Competitive Advantages for New Drug Portfolio", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/jyong-biotech-updates-market-access-000000493.html", "source_name": "PR Newswire", "published_at": "2026-04-29T00:00:00+00:00", "published_display": "29 Apr 2026 00:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Two plant-based prostate drug candidates move toward broader markets", "summary": "Jyong Biotech has advanced market access strategies for its botanical drugs Botreso and PCP, emphasizing their clinical efficacy, safety, and competitive advantages in manufacturing. Both drugs aim to address prostate health, with Botreso completing Phase III trials and PCP finis", "url": "https://www.stocktitan.net/news/MENS/jyong-biotech-updates-market-access-strategy-for-innovative-ubkj6k5p43gc.html", "source_name": "Stock Titan", "published_at": "2026-04-28T12:38:55", "published_display": "28 Apr 2026 12:38", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Short Interest in Jyong Biotech Ltd. (NASDAQ:MENS) Decreases By 43.2%", "summary": "Short interest in Jyong Biotech Ltd. (NASDAQ:MENS) significantly decreased by 43.2% in April, totaling 133,023 shares, which represents about 0.2% of its outstanding shares. This decline brings the short-interest ratio to approximately 1.0 days. Despite institutional investors li", "url": "https://www.marketbeat.com/instant-alerts/short-interest-in-jyong-biotech-ltd-nasdaqmens-decreases-by-432-2026-04-27/", "source_name": "MarketBeat", "published_at": "2026-04-28T01:39:27", "published_display": "28 Apr 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CEO Fu-Feng Kuo, Jyong Biotech Ltd.'s (NASDAQ:MENS) largest shareholder sees value of holdings go down 23% after recent drop", "summary": "", "url": "https://news.google.com/rss/articles/CBMidkFVX3lxTFBlQ1RRS0JuWHhUclVxSklTUi1VY3ZYSHlGd1BuUlVtdHBUbWtqVWNSR0cyZGxLbXBENFVFN2huNl9PRVhOVTI1cHNKS2lUUHB6SzFaQTBoazl5NV9OZmY2OGxFUXFXSDhRSzFJbHRIcHAwQmtybGc?oc=5", "source_name": "Market source", "published_at": "2026-02-10T08:00:00+00:00", "published_display": "10 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "After the recent decline, Jyong Biotech Ltd. (NASDAQ:MENS) CEO Fu-Feng Kuo's holdings have lost 33% of their value", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-29T08:00:00+00:00", "published_display": "29 Dec 2025 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jyong Biotech Responds to Share Price and Volume Movement", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxNbWNIS182Q0J3WTB4by13Mjk0ZjJtV2hUdVVKMTd0TlVGNEM0OFF6T01DYWllZVZFN2d3cEZ0T090cU41WWR0bjhCNlhtNkdrcDdHdTJTSGNRWTlUUGg2RXFad2ZYWndBWWlGeHFRdUhiNVd1SWlYN1lWdGc5Z3licU83MTFKNEFCVTV3UFVrSW5CMV8yUjJvR0NIck1zZG5XdWRjSkhKQzBCOTB5UEkzNHlVWl9DaVFHYnlfT2pQMG45UFhYVXNKeg?oc=5", "source_name": "GlobeNewswire", "published_at": "2025-12-19T08:00:00+00:00", "published_display": "19 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MENS Stock Price and Chart \u2014 NASDAQ:MENS", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE92bl9mOFBlOWpFNFVIR080ZUpPZ1JQN2tyM1N4Q2RXNEVjMW9mT0RIaEliUHRFOTVQdzBtTGVxQ1RVcEQ3ZkppVThWNjNRX05oT2NBZlR5R0w5Z0pC?oc=5", "source_name": "TradingView", "published_at": "2025-09-12T07:00:00+00:00", "published_display": "12 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy Jyong Biotech Ltd. (MENS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE1CaHl5SGNwX1JGVnZlaS1XdmRHS3dyRDBJSzhFLUx1aTFtTXR5TDdQcUVwaWQ2QXJ4NTZqSzRSeGRmcDJxa0VmbHhXV3VPWW05RW9BbHpBSTluU1F1cE01ZkxpbmRpZng5X3NJSw?oc=5", "source_name": "Zacks Investment Research", "published_at": "2025-07-31T20:22:27+00:00", "published_display": "31 Jul 2025 20:22", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 90, "total_relevant": 43, "sentiment_summary": {"positive": 12, "negative": 5, "neutral": 26, "score": 54, "total": 43, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 88, "events": [{"event": "general", "label": "Market update", "weight": 18.3, "count": 32}, {"event": "earnings", "label": "Earnings", "weight": 3.3, "count": 8}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}], "positive_events": 12, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 2.21, "latest_week": "2026-07-10", "one_week_move": -0.5, "four_week_move": 39.9, "twelve_week_move": -9.4, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.263023, "market_dynamics_buy_signal": false, "relative_strength": -90.566951, "fair_value_gap": -88.0, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 44.252, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-0.5% over one week, +39.9% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 56, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 6}, {"label": "TradingKey", "count": 6}, {"label": "GlobeNewswire", "count": 5}, {"label": "TradingView", "count": 5}, {"label": "Stock Titan", "count": 4}, {"label": "simplywall.st", "count": 3}, {"label": "Pluang", "count": 2}, {"label": "New York Post", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 35}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 32}, {"label": "Earnings", "count": 8}, {"label": "Capital return", "count": 1}, {"label": "Balance sheet", "count": 1}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "88/100 classification confidence."}, {"label": "Company focus", "value": "35", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-0.5% over one week, +39.9% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Doctor shares the \u2018most troubling trend\u2019 in men\u2019s health \u2014 and why biohacking is to blame"}], "updated_at": "2026-07-16T11:44:53.155599+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}